# KEYNOTE-189 (NCT02578680)

> Study of Pemetrexed+Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First Line Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-3475-189/KEYNOTE-189)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02578680
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Merck Sharp & Dohme LLC
- Conditions: Non-Small-Cell Lung Carcinoma
- Interventions: Pembrolizumab 200 mg; Cisplatin; Carboplatin; Pemetrexed; Folic acid 350-1000 μg; Vitamin B12 1000 μg; Dexamethasone 4 mg; Saline solution
- Enrollment: 616
- Primary outcome: Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as Assessed by Blinded Central Imaging
- Primary outcome: Overall Survival (OS)

## Indexed commentary on KEYNOTE-189 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=keynote-189-nct02578680